Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis & Forecasts (2015-2022): Strategic Business Report 2018 - Targeted Therapies Hog Limelight in AML Therapeutic Pipeline
DUBLIN, July 11, 2018 /PRNewswire/ --
The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand.
The report profiles 34 companies including many key and niche players such as:
- AbbVie Inc. (USA)
- Actinium Pharmaceuticals, Inc. (USA)
- Agios Pharmaceuticals, Inc. (USA)
- Amgen Inc. (USA)
- Astellas Pharma Inc. (Japan)
- Astex Pharmaceuticals, Inc. (USA)
- Celgene Corporation (USA)
- CTI BioPharma Corp. (USA)
- Cyclacel Pharmaceuticals, Inc. (USA)
- Daiichi Sankyo Company Limited (Japan)
- F. Hoffmann-La Roche AG (Switzerland)
- Immune Pharmaceuticals Inc. (USA)
- Janssen-Cilag Limited (UK)
- Jazz Pharmaceuticals plc (Ireland)
- MEI Pharma, Inc. (USA)
- Merus N.V. (The Netherlands)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Seattle Genetics, Inc. (USA)
- Stemline Therapeutics, Inc. (USA)
- Sunesis Pharmaceuticals, Inc. (USA)
- Tolero Pharmaceuticals, Inc. (USA)
Key Topics Covered
1. OUTLOOK
A Prelude
Growing Incidence and Poor Prognosis
A Fatal Concoction Creating Significant Unmet Needs
Inadequacies Marr Existing Therapeutics; Pipeline Therapies Offer Hope
Current and Future Analysis
Standard Mode of Treatment for AML
An Overview
Standard Approved Mode of Therapy for AML by Age Group
List of FDA-Approved Chemotherapy Drugs for Treatment of AML
Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
2. MARKET DYNAMICS
Growing Interest in the Genetics of AML
Targeted Therapies Hog Limelight in AML Therapeutic Pipeline
Select Major AML Therapeutics in Late-Stage Clinical Development
Select AML Therapeutics in Phase I and II Clinical Development
FLT3
The Most Advanced Natural Target
Chemotherapy Retains Developers' Interest; Better Chemotherapies on the Horizon
Vyxeos
The New Standard of Care in AML Treatment?
Select Benefits of Vyxeos in a Gist:
Drug Targeting Mutant IDH2 Enzyme Enters Pivotal Trials
Immunotherapies in Development too Show Promise
Annamycin Shows Promise as a Second Line Therapy for AML
Volasertib
the First in Molecular Targeting Agents for AML to Advance in Clinical Trials
ADCs' Clinical Trials Depict Mixed Results
Research Innovations/Findings in AML Therapeutics
Anti-CD98 Antibodies Offer Novel Approach
Inhibition of Metabolic Enzyme in AML Pathway Identified as an Promising Option
Personalized Vaccine Approach Invades AML Therapeutic R&D
Ceramide-based Therapeutic Targets Drug Resistance of AML
Fructose
Potential Target for AML Therapeutics
3. ACUTE MYELOID LEUKEMIA
THE DISEASE, EPIDEMIOLOGY, ETIOLOGY, SYMPTOMS, AND DIAGNOSIS
Understanding the Bone Marrow, and the Blood Cells
Blood Cells
White Cells
Red Cells
Platelets
Cancer
The Deadly Disease
Leukemia
A Disease of the Bone Marrow
Acute Leukemia
Chronic Leukemia
History
Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) Types
The FAB Classification of AML
WHO AML Classification
Epidemiology
Etiology of AML
Chemicals
Radiation
Smoking
Pre-existing Blood Disorders
Genetic Factors
AML Symptoms
Increased Bruising or Bleeding
Repeated or Frequent Infection
Anemia
AML Diagnosis
Full Blood Count
Bone Marrow Examination
Other Tests
4. TREATMENT OVERVIEW
5. DRUG APPROVALS/CLINICAL STUDIES
Immune Pharmaceuticals to Commence REMAIN Study
Precient Doses First Patient in Phase 1b/2 Clinical Trial of PTX-200
Stemline Therapeutics Presents Phase 2 Trial Data of SL-401
Helsinn and MEI Pharma Announce Phase 2 Trial results of Pracinostat and azacitidine
Daiichi Sankyo Announces Safety and Efficacy Data from Phase 1 Study of DS-3032
Pfizer Reveals Positive Phase 2 Study Results of glasdegib/PF-04449913
Teva's Trisenox Gains EU Approval for APL
Daiichi Sankyo Begins Patient Enrollment for Phase 3 QuANTUM Trial on Quizartinib
GlycoMimetics Doses First Patient in Phase 2 of GMI-1271
Seattle Genetics Initiates Phase 3 Clinical Trial for Vadastuximab Talirine
ImmunoGen Begins Clinical Study of IMGN779 for Treatment of AML
Agios Pharmaceuticals Initiates Phase 1/2 Study of AG-221 in Combination with VIDAZA
Bio-Path Announces Positive Phase II Results of BP1001
Sunesis Secures MAA Validation from EMA for Vosaroxin in AML
Agios Pharmaceuticals Initiates Phase 1b Study of AG-221
EMA Expands Indications of Celgene's VIDAZA
Astellas Pharma Doses First Patient in Phase 3 Registration Trial of ASP2215
OXiGENE Initiates Phase 1b/2 Trial of OXi4503
Seattle Genetics Initiates Phase 1b Clinical Trial of SGN-CD33A
Agios Pharmaceuticals Announces Safety and Efficacy Data from Phase 1 Trial of AG-120
MacroGenics Doses First Patient in Phase 1 Study of MGD006
6. RECENT INDUSTRY ACTIVITY
MacroGenics Received Orphan Drug Designation for AML Drug Candidate MGD006
FDA Puts Hold on Various Phase I Vadastuximab Trials
Arog Receives Orphan Drug Designation for Crenolanib in EU
FDA Grants Priority Review to Novartis' NDA for PKC412
Immune Pharmaceuticals Obtains FDA Assistance in Ceplene Pivotal Trial
Jazz Pharmaceuticals Begins NDA Submission for Vyxeos
Celgene to File NDA for AG-221
Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals
Celgene and Agios Enter into Collaboration with Abbott
Celyad Enters into Exclusive Licensing Agreement with Ono
Astex Enters into Clinical Trial Collaboration with Genentech
AbbVie's venetoclax Receives Orphan Drug Designation from EMA
Novartis Bags Breakthrough Status for Midostaurin Therapy in AML
AbbVie Obtains Breakthrough Therapy Designation for Venetoclax with HMAs in AML Treatment
FDA Clears Hybrigenics to Carry Out Phase II Trials on inecalcitol in AML Patients
Hybrigenics Gets Approval to Carry Out Phase II Trials on inecalcitol in AML Patients in France
Boehringer and Philogen Team Up to Develop AML Therapeutics
Astex Pharmaceuticals' SGI-110/guadecitabine Receives Orphan Drug Designation from FDA
Hybrigenics Obtains Orphan Drug Designation from FDA for Inecalcitol in AML Treatment
Daiichi Sankyo to Acquire Ambit Biosciences
Celgene Takes Over Rights to Blood Cancer Drugs of Agios
Karyopharm Therapeutics' Selinexor (KPT-330) Receives Orphan Drug Designation from FDA
Otsuka Buys Rights to Dacogen from Eisai
7. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Actinium Pharmaceuticals, Inc. (USA)
Agios Pharmaceuticals, Inc. (USA)
Amgen Inc. (USA)
Astellas Pharma Inc. (Japan)
Astex Pharmaceuticals, Inc. (USA)
Celgene Corporation (USA)
CTI BioPharma Corp. (USA)
Cyclacel Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company Limited (Japan)
F. Hoffmann-La Roche AG (Switzerland)
Immune Pharmaceuticals Inc. (USA)
Janssen-Cilag Limited (UK)
Jazz Pharmaceuticals plc (Ireland)
MEI Pharma, Inc. (USA)
Merus N.V. (The Netherlands)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Seattle Genetics, Inc. (USA)
Stemline Therapeutics, Inc. (USA)
Sunesis Pharmaceuticals, Inc. (USA)
Tolero Pharmaceuticals, Inc. (USA)
8. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 69 (including Divisions/Subsidiaries 73)
- The United States (40)
- Canada (3)
- Japan (3)
- Europe (24)
- France (3)
- Germany (2)
- The United Kingdom (5)
- Spain (1)
- Rest of Europe (13)
- Asia-Pacific (Excluding Japan) (1)
- Middle East (2)
For more information about this report visit https://www.researchandmarkets.com/research/8sqjrl/global_acute?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article